Brief primer on clostridium difficile infection costs, reimbursement, and government regulation

Christopher Frei, Grace Lee

    Research output: Contribution to journalArticle

    Abstract

    Clostridium difficile infection (CDI) is an important, costly, public health problem in the United States. Four economic studies have reported attributable costs of $3,000 to $12,000 per case. There is a great need for comparative-and cost-effectiveness studies of new CDI therapies. Such studies should include direct medical costs, indirect costs, lost opportunity costs, costs associated with disease recurrence, and quality of life assessments to help health care decision makers determine the value of these therapies.

    Original languageEnglish (US)
    Pages (from-to)S14-S18
    JournalHospital Pharmacy
    Volume48
    Issue number2 SUPPL. 1
    DOIs
    StatePublished - Feb 1 2013

    Keywords

    • Clostridium difficile infection
    • cost of illness
    • disease state management
    • health policy
    • pharmacoeconomics

    ASJC Scopus subject areas

    • Pharmacy
    • Pharmacology
    • Pharmacology (medical)

    Fingerprint Dive into the research topics of 'Brief primer on clostridium difficile infection costs, reimbursement, and government regulation'. Together they form a unique fingerprint.

    Cite this